Recent developments in adenosine receptor ligands and their potential as novel drugs

Biochimica et Biophysica Acta - Biomembranes

Volumn 1808, Issue 5, 2011, Pages 1290-1308

  Müller, Christa E ^a   Jacobson, Kenneth A ^b  

^a UNIVERSITY OF BONN   (Germany)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

Adenosine receptor; Agonist; Antagonist; Clinical trial; G protein coupled receptor; Medicinal chemistry

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 4 [7 [[1 [(3 CHLORO 2 THIENYL)METHYL]PROPYL]AMINO] 3H IMIDAZO[4,5 B]PYRIDIN 3 YL] N ETHYL 2,3 DIHYDROXYCYCLOPENTANECARBOXAMIDE; 6 N (2 HYDROXYCYCLOPENTYL)ADENOSINE; 6 N (3 IODOBENZYL)ADENOSINE 5' N METHYLCARBOXAMIDE; ADENOSINE A1 RECEPTOR AGONIST; ADENOSINE A1 RECEPTOR ANTAGONIST; ADENOSINE A2A RECEPTOR AGONIST; ADENOSINE A2A RECEPTOR ANTAGONIST; ADENOSINE A2B RECEPTOR AGONIST; ADENOSINE A2B RECEPTOR ANTAGONIST; ADENOSINE A3 RECEPTOR AGONIST; ADENOSINE A3 RECEPTOR ANTAGONIST; ADENOSINE RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; ADENOSINE RECEPTOR STIMULATING AGENT; APADENOSON; BINODENOSON; CAPADENOSON; CF 102; CV 3146; CVT 3619; GS 9667; GW 493838; NAXIFYLLINE; PRELADENANT; REGADENOSON; ROLOFYLLINE; SELODENOSON; TECADENOSON; TONAPOFYLLINE; UK 432097; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANGINA PECTORIS; ARTICLE; BINDING AFFINITY; DRUG ACTIVITY; DRUG INDICATION; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HEART ATRIUM FIBRILLATION; HEART MUSCLE PERFUSION; HUMAN; HYPERTRIGLYCERIDEMIA; IMAGING; INFLAMMATION; NEOPLASM; NEUROPATHIC PAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATION; PARKINSON DISEASE; PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN MODIFICATION; STRUCTURE ACTIVITY RELATION;

ANIMALS; DRUG DESIGN; HUMANS; LIGANDS; PROTEIN BINDING; PURINERGIC P1 RECEPTOR AGONISTS; PURINERGIC P1 RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P1;

EID: 79952027612     PISSN: 00052736     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbamem.2010.12.017     Document Type: Review

References (192)

1. B.B. Fredholm, A.P. IJzerman, K.A. Jacobson, J. Linden, C.E. Müller, Nomenclature and classification of adenosine receptors - an update. Pharmacol. Rev., (in press).
2. B.B. Fredholm, A.P. IJzerman, K.A. Jacobson, K.N. Klotz, and J. Linden International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors Pharmacol. Rev. 53 2001 527 552 (Pubitemid 33136237)
3. 2A adenosine receptor bound to an antagonist Science 322 2008 1211 1217
4. 2A receptor antagonists J. Med. Chem. 53 2010 1799 1809
5. 2A receptor ligands J. Med. Chem. 53 2010 3748 3755
6. R. Franco, V. Casadó, A. Cortés, K. Pérez-Capote, J. Mallol, E. Canela, S. Ferré, and C. Lluis Novel pharmacological targets based on receptor heteromers Brain Res. Rev. 58 2008 475 482
7. 2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer J. Biol. Chem. 278 2003 46741 46749 (Pubitemid 37452253)
8. P. Carriba, G. Navarro, F. Ciruela, S. Ferré, V. Casadó, L. Agnati, A. Cortés, J. Mallol, K. Fuxe, E.I. Canela, C. Lluis, and R. Franco Detection of heteromerization of more than two proteins by sequential BRET-FRET Nat. Meth. 5 2008 727 733
9. S. Ferré, R. Baler, M. Bouvier, M.G. Caron, L.A. Devi, T. Durroux, K. Fuxe, S.R. George, J.A. Javitch, M.J. Lohse, K. Mackie, G. Milligan, K.D. Pfleger, J.P. Pin, N.D. Volkow, M. Waldhoer, A.S. Woods, and R. Franco Building a new conceptual framework for receptor heteromers Nat. Chem. Biol. 5 2009 131 134
10. 1 receptors form functionally interacting heteromeric complexes Proc. Natl Acad. Sci. USA 97 2000 8606 8611 (Pubitemid 30639720)
11. 2B adenosine receptor agonists Purinergic Signal. 5 2009 3 19
12. 2B adenosine receptor antagonists as clinical candidates Purinergic Signal. 5 2009 21 29
13. 2B receptor ligands: past, present and future trends Curr. Top. Med. Chem. 10 2010 923 940
14. 2B receptor antagonists and a new radioligand with subnanomolar affinity and subtype specificity J. Med. Chem. 52 2009 3994 4006
15. C.E. Müller, K.A. Jacobson, Xanthines as adenosine receptor antagonists. In Methylxanthines. In Handbook of Experimental Pharmacology, B.B. Fredholm, ed., Springer, 200 (2011) 151-199.
16. 3 adenosine receptor antagonists Mini-Rev. Med. Chem. 1 2001 417 427
17. C.E. Müller Medicinal chemistry of adenosine A3 receptor ligands Curr. Top. Med. Chem. 3 2003 445 462
18. 1-adenosine receptor antagonists Exp. Opin. Ther. Pat. 7 1997 419 440 (Pubitemid 27225519)
19. 3 adenosine receptors Biochem. Pharmacol. 65 2003 1675 1684 (Pubitemid 36577280)
20. 1 adenosine receptors FEBS Lett. 209 1986 122 128 (Pubitemid 17224579)
21. C.E. Müller, and T. Scior Adenosine receptors and their modulators Pharm. Acta Helv. 68 1993 77 111 (Pubitemid 23332880)
22. 3 adenosine receptor agonist, in healthy young men Int. J. Clin. Pharmacol. Ther. 42 2004 534 542 (Pubitemid 39386793)
23. E.C. Klaasse, A.P. IJzerman, W.J. de Grip, and M.W. Beukers Internalization and desensitization of adenosine receptors Purinergic Signal. 4 2008 21 37
24. C.E. Müller, and B. Stein Adenosine receptor antagonists: structures and potential therapeutic applications Curr. Pharm. Des. 2 1996 501 530 (Pubitemid 126471649)
25. S. Weyler, F. Fülle, M. Diekmann, B. Schumacher, S. Hinz, K.N. Klotz, and C.E. Müller Improving potency, selectivity, and water-solubility of adenosine A1 receptor antagonists: xanthines modified at position 3 and related pyrimido[1,2,3-cd]purinediones ChemMedChem 1 2006 891 902 (Pubitemid 44384549)
26. 2A-selective adenosine receptor antagonists J. Med. Chem. 43 2000 440 448 (Pubitemid 30102084)
27. 2A receptor antagonist MSX-2 Molecules 13 2008 348 359
28. C.E. Müller, M. Thorand, R. Qurishi, M. Diekmann, K.A. Jacobson, W.L. Padgett, and J.W. Daly Imidazo[2,1-i]purin-5-ones and related tricyclic water-soluble purine derivatives: potent A2A- and A3-adenosine receptor antagonists J. Med. Chem. 45 2002 3440 3450 (Pubitemid 34824031)
29. M.H. Holschbach, and R.A. Olsson Applications of adenosine receptor ligands in medical imaging by positron emission tomography Curr. Pharm. Des. 8 2002 2345 2352 (Pubitemid 35331540)
30. 3 adenosine receptors exist within heterogeneous complexes in membrane microdomains of individual living cells FASEB J. 22 2008 850 886
31. 1 receptor agonists that allow quantification of single living cells J. Med. Chem. 50 2007 782 793 (Pubitemid 46335649)
32. 2A adenosine receptor: application to a fluorescence polarization-based receptor binding assay Biochem. Pharmacol. 80 2010 506 511
33. U. Rosentreter, R. Henning, M. Bauser, T. Kramer, A. Vaupel, W. Hubsch, K. Dembowsky, O. Salcher-Schrauf-Stetter, J.P. Stasch, T. Krahn, E. Petzborn, Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and the use thereof. WO Pat. 2001/025210.
34. 2B receptor with an improved selectivity profile compared to the reference agonist N-ethylcarboxamidoadenosine J. Med. Chem. 47 2004 3707 3709 (Pubitemid 38900337)
35. L. Yan, J.C. Burbiel, A. Maaß, and C.E. Müller Adenosine receptor agonists: from basic medicinal chemistry to clinical development Exp. Opin. Emerg. Drugs 8 2003 537 576 (Pubitemid 37522665)
36. 1 adenosine receptor antagonists, agonists, and allosteric enhancers Handb. Exp. Pharmacol. 193 2009 25 58 Review
37. 3 receptor Eur. J. Pharmacol. 443 2002 39 42 (Pubitemid 34603595)
38. 2A receptor ligands Handb. Exp. Pharmacol. 193 2009 59 98
39. 2A receptor ligands: past, present and future trends Curr. Top. Med. Chem. 10 2010 902 922
40. 2A receptor dynamics studied with the novel fluorescent agonist Alexa488-APEC Eur. J. Pharmacol. 590 2008 36 42
41. Y. Kim, B. Hechler, Z.G. Gao, C. Gachet, and K.A. Jacobson PEGylated dendritic unimolecular micelles as versatile carriers for ligands of G protein-coupled receptors Bioconjug. Chem. 20 2009 1888 1898
42. 2A adenosine receptor crystallographic structure J. Med. Chem. 52 2009 3284 3292
43. 2A receptor J. Comput. Aided Mol. Des. 23 2009 807 828
44. 2A agonists and comparison of inhaled pharmacokinetics in a preclinical model with clinical pharmacokinetic data Bioorg. Med. Chem. Lett. 19 2009 4471 4475
45. 2A receptor agonists activated by ecto-5′-nucleotidase J. Med. Chem. 52 2009 7669 7677
46. 2B adenosine receptor agonists J. Med. Chem. 50 2007 374 380 (Pubitemid 46147717)
47. 6,5′- substituted adenosine derivatives with potent activity at the A2B adenosine receptor J. Med. Chem. 50 2007 1810 1827 (Pubitemid 46626592)
48. M.V. Cohen, and J.M. Downey Adenosine: trigger and mediator of cardioprotection Basic Res. Cardiol. 103 2008 203 215
49. 2B adenosine receptors Circulation 115 2007 1581 1590 (Pubitemid 46648643)
50. 3 adenosine receptor: agonists, antagonists, and receptor engineering HEP Adenosine Receptors in Health and Disease C. Wilson, J. Mustafa, Handb. Exp. Pharmacol. 193 2009 Springer 123 159
51. 3 adenosine receptor agonists Bioorg. Med. Chem. 18 2010 3078 3087
52. 3 receptor J. Med. Chem. 52 2009 7897 7900
53. 3 adenosine receptor J. Med. Chem. 46 2003 3775 3777 (Pubitemid 37034129)
54. 6-disubstituted adenine nucleosides as highly potent and selective A3 adenosine receptor agonists J. Med. Chem. 48 2005 1745 1758 (Pubitemid 40396308)
55. 3 adenosine receptor antagonists derived from nucleosides containing a bicyclo[3.1.0]hexane ring system Bioorg. Med. Chem. 16 2008 8546 8556
56. A.M. Klutz, Z.G. Gao, J. Lloyd, A. Shainberg, and K.A. Jacobson Enhanced A3 adenosine receptor selectivity of multivalent nucleoside-dendrimer conjugates J. Nanobiotechnol. 6 2008 12
57. P.G. Baraldi, M.A. Tabrizi, S. Gessi, and P.A. Borea Adenosine receptor antagonists: translating medicinal chemistry and pharmacology into clinical utility Chem. Rev. 108 2008 238 263 (Pubitemid 351176408)
58. S. Moro, Z.G. Gao, K.A. Jacobson, and G. Spalluto Progress in the pursuit of therapeutic adenosine receptor antagonists Med. Res. Rev. 26 2006 131 159 (Pubitemid 43334639)
59. S. Schenone, C. Brullo, F. Musumeci, O. Bruno, and M. Botta A1 receptors ligands: past, present, and future trends Curr. Top. Med. Chem. 10 2010 878 901
60. M.T. Slawski, and M.M. Givertz Rolofylline: a selective adenosine 1 receptor antagonist for the treatment of heart failure Exp. Opin. Pharmacother. 10 2009 311 322
61. J.R. Pfister, L. Belardinelli, G. Lee, R.T. Lum, P. Milner, W.C. Stanley, J. Linden, S.P. Baker, and G. Schreiner Synthesis and biological evaluation of the enantiomers of the potent and selective A1-adenosine antagonist 1,3-dipropyl-8-[2-(5,6-epoxynorbornyl)]xanthin J. Med. Chem. 40 1997 1773 1778 (Pubitemid 27251266)
62. C.E. Müller Prodrug approaches for enhancing the bioavailability of drugs with low solubility Chem. Biodivers. 6 2009 2071 2083
63. 1 receptor antagonists Bioorg. Med. Chem. 18 2010 2195 2203
64. 2A receptors: a new strategy for basal ganglia disorders Recent Pat. CNS Drug Discov. 2 2007 1 21 (Pubitemid 46729088)
65. 2A receptors: a new strategy for basal ganglia disorders, Frontiers in CNS Drug Discov 1 (2010) 304-341.
66. 2A receptor antagonists for the treatment of Parkinson's disease Curr. Opin. Drug Discov. Devel. 13 2010 466 480
67. 2B adenosine receptor antagonists J. Pharmacol. Exp. Ther. 308 2004 358 366 (Pubitemid 38090738)
68. A. Bilkei-Gorzo, O.M. Abo-Salem, A.M. Hayallah, K. Michel, C.E. Müller, and A. Zimmer Naunyn Schmiedebergs Arch. Pharmacol. 377 2008 65 76
69. 2A antagonist MSX-3 reverses the effects of the dopamine antagonist haloperidol on effort-related decision making in a T-maze cost/benefit procedure Psychopharmacology 204 2009 103 112
70. 2A antagonist MSX-3 reverses the effort-related effects of dopamine blockade: differential interaction with D1 and D2 family antagonists Psychopharmacology 203 2009 489 499
71. 2A receptors in brain Eur. J. Pharmacol. 411 2001 205 210 (Pubitemid 32119590)
72. G. Pastorin, S. Federico, S. Paoletta, M. Corradino, F. Cateni, B. Cacciari, K.-N. Klotz, Z.-G. Gao, K.A. Jacobson, G. Spalluto, and S. Moro Synthesis and pharmacological characterization of a new series of 5,7-disubstituted-[1,2,4]triazolo[1,5-a][1,3,5]triazine derivatives as adenosine receptor antagonists: a preliminary inspection of ligand-receptor recognition process Bioorg. Med. Chem. 18 2010 2524 2536
73. 2A receptor system using positron emission tomography J. Med. Chem. 43 2000 4359 4362 (Pubitemid 32046859)
74. 2A receptor antagonists. Part II: synthesis and structure-activity relationships of novel benzofuran derivatives Bioorg. Med. Chem. Lett. 20 2010 3768 3771
75. P.M. Luthra, C.B. Mishra, P.K. Jha, and S.K. Barodia Synthesis of novel 7-imino-2-thioxo-3,7-dihydro-2H-thiazolo[4,5-d]pyrimidine derivatives as adenosine A2A receptor antagonists Bioorg. Med. Chem. 20 2010 1214 1218
76. C.B. Mishra, S.K. Barodia, A. Prakash, J.B.S. Kumar, and P.M. Luthra Novel 8-(furan-2-yl)-3-substituted thiazolo[5,4-e][1,2,4]triazolo[1,5-c] pyrimidine-2(3H)-thione derivatives as potential adenosine A2A receptor antagonists Bioorg. Med. Chem. 18 2010 2491 2500
77. S. Moro, F. Deflorian, M. Bacilieri, and G. Spalluto Ligand-based homology modeling as attractive tool to inspect GPCR structural plasticity Curr. Pharm. Des. 12 2006 2175 2185 (Pubitemid 43891410)
78. 3 adenosine receptor Biochem. Pharmacol. 79 2010 967 973
79. 3 adenosine receptor antagonists J. Med. Chem. 51 2008 6609 6613
80. 3 adenosine receptors lower mouse intraocular pressure and act across species Exp. Eye Res. 90 2010 146 154
81. P.N. Zannikos, B.K. Jensen, B.X. Boutouyrie, L. Tripp, L. Yongyi, T. McGowan, S.A. Waldman, and H.E. Greenberg Pharmacokinetics and safety of single intravenous infusions of the adenosine agonist, AMP 579, in patients with end-stage renal insufficiency J. Clin. Pharmacol. 40 2000 745 751
82. S.L. Kopecky, R.J. Aviles, M.R. Bell, J.K. Lobl, D. Tipping, G. Frommell, K. Ramsey, A.E. Holland, M. Midei, A. Jain, M. Kellett, and R.J. Gibbons A randomized, double-blinded, placebo-controlled, dose-ranging study measuring the effect of an adenosine agonist on infarct size reduction in patients undergoing primary percutaneous transluminal coronary angioplasty: the ADMIRE (AmP579 Delivery for Myocardial Infarction REduction) study Am. Heart J. 146 2003 146 152 (Pubitemid 36851314)
83. 2b- adenosine receptor agonist in human 293 cells and rabbit hearts Basic Res. Cardiol. 105 2010 129 137
84. T. Porkka-Heiskanen, L. Alanko, A. Kalinchuk, and D. Stenberg Adenosine and sleep Sleep Med. Rev. 6 2002 321 332 (Pubitemid 36527690)
85. 1 adenosine receptor binding in the human brain: a positron emission tomography study J. Neurosci. 27 2007 2410 2415 (Pubitemid 46340969)
86. T.M. Palmer, and M.A. Trevethick Suppression of inflammatory and immune responses by the A2A adenosine receptor: an introduction Br. J. Pharmacol. 153 2008 S27 S34
87. D. Yang, M. Koupenova, D.J. McCrann, K.J. Kopeikina, H.M. Kagan, B.M. Schreiber, and K. Ravid The A2b adenosine receptor protects against vascular injury Proc. Natl Acad. Sci. USA 105 2008 792 796 (Pubitemid 351171787)
88. J. Guzman, J.G. Yu, Z. Suntres, A. Bozarov, H. Cooke, N. Javed, H. Auer, J. Palatini, H.H. Hassanain, A.J. Cardounel, A. Javed, I. Grants, J.E. Wunderlich, and F.L. Christofi Inflamm. Bowel Dis. 12 2006 766 789
89. V.L. Kolachala, R. Bajaj, M. Chalasani, and S.V. Sitaraman Purinergic receptors in gastrointestinal inflammation Am. J. Physiol. Gastrointest. Liver Physiol. 294 2008 G401 G410
90. 3 adenosine receptor in peripheral blood mononuclear cells in rheumatoid arthritis: involvement of nuclear factor-kappaB in mediating receptor level J. Rheumatol. 34 2007 20 26 (Pubitemid 46106558)
91. 1 receptor agonist, in spontaneously hypertensive rat complicated with hyperglycemia Diab. Res. Clin. Pract. 39 1998 3 9 (Pubitemid 28179238)
92. C. Lauro, R. Cipriani, M. Catalano, F. Trettel, G. Chece, V. Brusadin, L. Antonilli, N. van Rooijen, F. Eusebi, B.B. Bredholm, and C. Limatola Adenosine A1 receptors and microglial cells mediate CX3CL1-induced protection of hippocampal neurons against Glu-induced death Neuropsychopharmacology 35 2010 1550 1559
93. 1 agonists with diminished hypotensive effects J. Med. Chem. 42 1999 3463 3477 (Pubitemid 29445081)
94. 1 receptor agonist GR79236 on trigeminal nociception with blink reflex recordings in healthy human subjects Cephalalgia 23 2003 287 292 (Pubitemid 36577947)
95. B. Shah, S. Rohatagi, C. Natarajan, S. Kirkesseli, R. Baybutt, and B.K.I. Jensen Pharmacokinetics, pharmacodynamics, and safety of a lipid-lowering adenosine A1 agonist, RPR749, in healthy subjects Am. J. Ther. 11 2004 175 189
96. 1 adenosine receptor agonists from a molecular perspective and their potential use as chronic ventricular rate control agents during atrial fibrillation (AF) Curr. Top. Med. Chem. 4 2004 839 854 (Pubitemid 38854842)
97. 2A receptor activation attenuates inflammation and injury in diabetic nephropathy Am. J. Physiol. Renal. Physiol. 290 2006 F828 F837
98. 2A receptor stimulation increases angiogenesis by down-regulating production of the antiangiogenic matrix protein thrombospondin 1 Mol. Pharmacol. 67 2005 1406 1413 (Pubitemid 40594139)
99. 2A receptor agonist binodenoson for pharmacological stress as an adjunct to myocardial perfusion imaging Circulation 109 2004 457 464 (Pubitemid 38168506)
100. 2A receptor agonists Curr. Cardiol. Rep. 8 2006 119 122
101. A.E. Iskandrian, T.M. Bateman, L. Belardinelli, B. Blackburn, M.D. Cerqueira, R.C. Hendel, H. Lieu, J.J. Mahmarian, A. Olmsted, S.R. Underwood, J. Vitola, and W. Wang Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial J. Nucl. Cardiol. 14 2007 645 658 (Pubitemid 47355078)
102. I. Avni, H.J. Garzozi, I.S. Barequet, F. Segev, D. Varssano, G. Sartani, N. Chetrit, E. Bakshi, D. Zadok, O. Tomkins, G. Litvin, K.A. Jacobson, S. Fishman, Z. Harpaz, M. Farbstein, S. Bar-Yehuda, M.H. Silverman, W.D. Kerns, I. Cohn, and P. Fishman Treatment of dry eye syndrome with orally-administered CF101: data from a phase 2 clinical trial Ophthalmology 117 2010 1287 1293
103. 6-(2,5-dichlorobenzyl)-3′-aminoadenosine-5′- N-methylcarboxamide] protects against myocardial ischemia/reperfusion injury via the sarcolemmal ATP-sensitive potassium channel J. Pharmacol. Exp. Ther. 324 2008 234 243 (Pubitemid 350294150)
104. M. Skouroliakou, F. Bacopoulou, and S.L. Markantonis Caffeine versus theophylline for apnea of prematurity: a randomized controlled trial J. Paediatr. Child Health 45 2009 587 592
105. R. Polosa, and S.T. Holgate Adenosine receptors as promising therapeutic targets for drug development in chronic airway inflammation Curr. Drug Targets 7 2006 699 706 (Pubitemid 43827266)
106. 1 antagonists and the cardiorenal syndrome Curr. Heart Fail. Rep. 5 2008 105 109
107. J. Che, E.S. Chan, and B.N. Cronstein Adenosine A2A receptor occupancy stimulates collagen expression by hepatic stellate cells via pathways involving protein kinase A, Src, and extracellular signal-regulated kinases 1/2 signaling cascade or p38 mitogen-activated protein kinase signaling pathway Mol. Pharmacol. 72 2007 1626 1636 (Pubitemid 350146100)
108. 3 adenosine-receptor antagonist MRS 1292 inhibits adenosine-triggered human nonpigmented ciliary epithelial cell fluid release and reduces mouse intraocular pressure Curr. Eye Res. 30 2005 747 754 (Pubitemid 41426501)
109. K.A. Jacobson, and Z.G. Gao Adenosine receptors as therapeutic targets Nat. Rev. Drug Discov. 5 2006 247 264 (Pubitemid 43336037)
110. N. Arispe, J. Ma, K.A. Jacobson, and H.B. Pollard Direct activation of cystic fibrosis transmembrane conductance regulator channels by 8-cyclopentyl-1,3-dipropylxanthine (CPX) and 1,3-diallyl-8-cyclohexylxanthine (DAX) J. Biol. Chem. 273 1998 5727 5734 (Pubitemid 28124046)
111. C.N. Wilson Adenosine receptors and asthma in humans Br. J. Pharmacol. 155 2008 475 486
112. S. Hess Recent advances in adenosine receptor antagonist research Exp. Opin. Ther. Pat. 11 2001 1533 1561 (Pubitemid 33026047)
113. 1 receptor antagonist Eur. J. Pharmacol. 279 1995 217 225
114. 1 receptor antagonists in clinical research and development, Kidney Int. 78 (2010) 438-445.
115. 2A receptor antagonist istradefylline (KW6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005) Ann. Neurol. 63 2008 295 302 (Pubitemid 351499859)
116. 3 antagonist, does not attenuate AMP challenge in subjects with asthma Proc. Am. Thorac. Soc. 2007 A682
117. T. Okamura, Y. Kurogi, K. Hashimoto, S. Sato, H. Nishikawa, K. Kiryu, and Y. Nagao Structure-activity relationships of adenosine A3 receptor ligands: new potential therapy for the treatment of glaucoma Bioorg. Med. Chem. Lett. 14 2004 3775 3779 (Pubitemid 38765172)
118. 3 adenosine receptor: pharmacology and role in disease Handb. Exp. Pharmacol. 193 2009 297 327
119. A. Bauer, and K. Ishiwata Adenosine receptor ligands and PET imaging in the CNS Handb. Exp. Pharmacol. 2009 617 642
120. 2A antagonist Appl. Radiat. Isot. 47 1996 507 511
121. J. Noguchi, K. Ishiwata, S. Wakabayashi, T. Nariai, S. Shumiya, S. Ishii, H. Toyama, K. Endo, F. Suzuki, and M. Senda Evaluation of carbon-11-labeled KF17837: a potential CNS adenosine A2a receptor ligand J. Nucl. Med. 39 1998 498 503 (Pubitemid 28136852)
122. 2A receptors by PET App. Radiat. Isot. 50 1999 887 893 (Pubitemid 29138975)
123. 2A receptor in the central nervous system Ann. Nucl. Med. 14 2000 247 253
124. 2A receptor ligand J. Nucl. Med. 41 2000 345 354 (Pubitemid 30091357)
125. 11C]SCH442416 Eur. J. Nucl. Med. Mol. Imaging 32 2005 405 413 (Pubitemid 40591172)
126. 3 receptor Nucl. Med. Biol. 35 2008 61 66 (Pubitemid 350298248)
127. 3 adenosine receptor ligands for positron emission tomography Nucl. Med. Biol. 36 2009 3 10
128. L. Yan, J.C. Burbiel, A. Maaß, and C.E. Müller Adenosine receptor agonists: from basic medicinal chemistry to clinical development Exp. Opin. Emerg. Drugs 8 2003 537 576 (Pubitemid 37522665)
129. 2 adenosine receptors Pharmacology 46 1993 91 100 (Pubitemid 23041148)
130. R.F. Bruns Adenosine receptor activation in human fibroblasts: nucleoside agonists and antagonists Can. J. Physiol. Pharmacol. 58 1980 673 691 (Pubitemid 10090366)
131. L.E. Brackett, and J.W. Daly Functional characterization of the A2b adenosine receptor in NIH 3T3 fibroblasts Biochem. Pharmacol. 47 1994 801 814
132. 3 adenosine receptor Proc. Natl Acad. Sci. 90 1993 10365 10369 (Pubitemid 23328313)
133. 3 adenosine binding site Mol. Pharmacol. 45 1994 1101 1111 (Pubitemid 24195566)
134. 3 Adenosine Receptors From Cell Biology to Pharmacology 2010 257 280
135. 1 adenosine receptor agonists and their potential therapeutic applications Expert Opin. Investig. Drugs 17 2008 1901 1910
136. G.J. Smits, M. McVey, B.F. Cox, M.H. Perrone, and K.L. Clark Cardioprotective effects of the novel adenosine A1/A2 receptor agonist AMP 579 in a porcine model of myocardial infarction J. Pharmacol. Exp. Ther. 286 1998 611 618 (Pubitemid 29003446)
137. 6-cyclohexyladenosine Synth. Commun. 26 1996 3967 3977 (Pubitemid 26323259)
138. 2A receptor agonists Bioorg. Med. Chem. Lett. 20 2010 1219 1224
139. M.D. Valls, B.N. Cronstein, and M.C. Montesinos Adenosine receptor agonists for promotion of dermal wound healing Biochem. Pharmacol. 77 8 2009 1117 1124
140. A. Kuno, S.D. Critz, L. Cui, V. Solodushko, X.M. Yang, T. Krahn, B. Albrecht, S. Philipp, M.V. Cohen, and J.M. Downey Protein kinase C protects preconditioned rabbit hearts by increasing sensitivity of adenosine A2b-dependent signaling during early reperfusion J. Mol. Cell. Cardiol. 43 2007 262 271 (Pubitemid 47315714)
141. 2B adenosine receptor from mouse, rabbit, and dog J. Pharmacol. Exp. Ther. 329 2009 2 13
142. 3 adenosine receptor J. Med. Chem. 49 2006 273 281 (Pubitemid 43077340)
143. 3 receptor-selective agonists Bioorg. Med. Chem. Lett. 18 2008 2813 2819 (Pubitemid 351608886)
144. 6-substituted adenosine 5′-N- methyluronamides with high selectivity for human adenosine A3 receptors reduce ischemic myocardial injury Am. J. Physiol. Heart Circ. Physiol. 285 2003 H2780 H2787
145. K.A. Jacobson, A.P. IJzerman, and J. Linden 1,3-Dialkylxanthine derivatives having high potency as antagonists at human A2B adenosine receptors Drug Dev. Res. 47 1999 45 53 (Pubitemid 29293572)
146. 2-adenosine receptor antagonists J. Med. Chem. 37 1994 1526 1534 (Pubitemid 24174091)
147. J.W. Daly, I. Hide, C.E. Müller, and M. Shamim Caffeine analogs: structure-activity relationships at adenosine receptors Pharmacology 42 1991 309 321
148. 2A adenosine receptors Eur. J. Pharm. Sci. 10 2000 259 265 (Pubitemid 30317461)
149. 2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions J. Med. Chem. 45 2002 2131 2138 (Pubitemid 34525793)
150. 2B receptors by radioligand binding studies Purinergic Signal. 2 2006 559 571 (Pubitemid 44363752)
151. C.E. Müller, D. Shi, M. Manning Jr., and J.W. Daly Synthesis of paraxanthine analogs (1,7-disubstituted xanthines) and other xanthines unsubstituted at the 3-position: structure-activity relationships at adenosine receptors J. Med. Chem. 36 1993 3341 3349 (Pubitemid 23335698)
152. K.N. Klotz, H. Vogt, and H. Tawfik-Schlieper Comparison of adenosine receptors in brain from different species by radioligand binding and photoaffinity labelling Naunyn Schmiedebergs Arch. Pharmacol. 343 1991 196 201
153. 2B receptors from rat, guinea pig and dog Eur. J. Pharmacol. 475 2003 79 84 (Pubitemid 37088009)
154. 1-adenosine receptors Bioconjug. Chem. 6 1995 255 263
155. 2B receptor Mol. Pharmacol. 52 1997 846 860 (Pubitemid 27484178)
156. A.M. Hayallah, J. Sandoval-Ramírez, U. Reith, U. Schobert, B. Preiss, B. Schumacher, J.W. Daly, and C.E. Müller 1,8-Disubstituted xanthine derivatives: synthesis of potent A2B-selective adenosine receptor antagonists J. Med. Chem. 45 2002 1500 1510 (Pubitemid 34246113)
157. 1 receptor antagonists Bioorg. Med. Chem. 14 2006 3654 3661
158. 1 receptor antagonists J. Med. Chem. 49 2006 7119 7131 (Pubitemid 44885997)
159. S.A. Doggrell BG-9928 (Biogen Idec) Curr. Opin. Investig. Drugs 6 2005 962 968
160. 1 receptor antagonist SLV320 reduces myocardial fibrosis in rats with 5/6 nephrectomy without affecting blood pressure Br. J. Pharmacol. 151 2007 1025 1032 (Pubitemid 47195534)
161. P.C. Obiefuna, V.K. Batra, A. Nadeem, P. Borron, C.N.H. Wilson, and S.J. Mustafa A novel A1 adenosine receptor antagonist, L-97-1 [3-[2-(4-aminophenyl)- ethyl]-8-benzyl-7-{2-ethyl-(2-hydroxy-ethyl)-amino]-ethyl}-1-propyl-3, 7-dihydro-purine-2,6-dione], reduces allergic responses to house dust mite in an allergic rabbit model of asthma J. Pharmacol. Exp. Ther. 315 2005 329 336 (Pubitemid 41380528)
162. 2A receptor selective antagonist KW6002: research toward a novel nondopaminergic therapy for Parkinson's disease Neurology 61 2003 S97 S100
163. 2A antagonists with potent anti-cataleptic activity Bioorg. Med. Chem. Lett. 7 1997 2349 2352 (Pubitemid 27412483)
164. J. Pretorius, S.F. Malan, N. Castagnoli Jr., J.J. Bergh, and J.P. Petzer Dual inhibition of monoamine oxidase B and antagonism of the adenosine A2A receptor by (E,E)-8-(4-phenylbutadien-1-yl)caffeine analogues Bioorg. Med. Chem. 16 2008 8676 8684
165. 2-selective adenosine antagonists J. Med. Chem. 36 1993 1333 1342 (Pubitemid 23164489)
166. R.J. Gillespie, S.J. Bamford, R. Botting, M. Comer, S. Denny, S. Gaur, M. Griffin, A.M. Jordan, A.R. Knight, J. Lerpiniere, S. Leonardi, S. Lightowler, S. McAteer, A. Merrett, A. Misra, A. Padfield, M. Reece, M. Saadi, D.L. Selwood, G.C. Stratton, D. Surry, R. Todd, X. Tong, V. Ruston, R. Upton, and S.M. Weiss Antagonists of the human A2A receptor. 4. Design, synthesis, and preclinical evaluation of 7-aryltriazolo[4,5-d]pyrimidines J. Med. Chem. 52 2009 33 47
167. P. Minetti, M.O. Tinti, P. Carminati, M. Castorina, M.A. Di Cesare, S. Di Serio, G. Gallo, O. Ghirardi, F. Giorgi, L. Giorgi, G. Piersanti, F. Bartoccini, and G. Tarzia 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6- ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization J. Med. Chem. 48 2005 6887 6896 (Pubitemid 41533110)
168. 2B adenosine receptors J. Med. Chem. 43 2000 1165 1172 (Pubitemid 30173742)
169. 2B adenosine receptor antagonists J. Med. Chem. 47 2004 1434 1447 (Pubitemid 38327470)
170. 2B adenosine receptor antagonist as a clinical candidate for chronic inflammatory airway diseases J. Med. Chem. 51 2008 2267 2278 (Pubitemid 351503282)
171. P. Eastwood, J. Gonzalez, S. Paredes, A. Nueda, T. Domenech, J. Alberti, and B. Vidal Discovery of N-(5,6-diarylpyridin-2-yl)amide derivatives as potent and selective A2B adenosine receptor antagonists Bioorg. Med. Chem. Lett. 20 2010 1697 1700
172. B. Vidal, A. Nueda, C. Esteve, T. Domenech, S. Benito, R.F. Reinoso, M. Pont, M. Clabet, R. Lopez, M.I. Cadavid, M.I. Loza, A. Cardenas, N. Godessart, J. Beleta, G. Varrellow, and H. Ryder Discovery and characterization of 4′-(2-furyl)-N-pyridin-3-yl-4,5′-bipyridmidin-2′-amine (LAS38096), a potent, selective, and efficacious A2B adenosine receptor antagonist J. Med. Chem. 50 2007 2732 2736 (Pubitemid 46896081)
173. 2B receptor Bioorg. Med. Chem. Lett. 19 2009 5945 5949
174. 2B adenosine receptor antagonists Bioorg. Med. Chem. Lett. 20 2010 4140 4146
175. 2B adenosine receptor antagonists via bioisosteric amide replacement Bioorg. Med. Chem. Lett. 20 2010 1634 1637
176. 2B receptors Biochem. Pharmacol. 68 2004 305 312 (Pubitemid 38757699)
177. 3 Adenosine Receptors From Cell Biology to Pharmacology 2010 Chapter 1
178. 3 adenosine receptor antagonists: new insights into structure-affinity relationship and receptor-antagonist recognition J. Med. Chem. 53 2010 3361 3375
179. 3 receptor J. Med. Chem. 43 2000 2227 2238 (Pubitemid 30354547)
180. M. Saki, H. Tsumuki, H. Nonaka, J. Shimada, and M. Ichimura KF26777 (2-(4-bromophenyl)-7,8-dihydro-4-propyl-1H-imidazo[2,1-i]purin-5(4H)-one dihydrochloride), a new potent and selective adenosine A3 receptor antagonist Eur. J. Pharmacol. 444 2002 133 141 (Pubitemid 34626830)
181. V. Ozola, M. Thorand, M. Diekmann, R. Qurishi, B. Schumacher, K.A. Jacobson, and C.E. Müller 2-Phenylimidazo[2,1-i]purin-5-ones: structure-activity relationships and characterization of potent and selective inverse agonists at human A3 adenosine receptors Bioorg. Med. Chem. 11 2003 347 356 (Pubitemid 36051025)
182. C.E. Müller, M. Diekmann, M. Thorand, and V. Ozola [3H]8-Ethyl-4-methyl-2-phenyl-(8R)-4,5,7,8-tetrahydro-1H-imidazo[2,1-i] purin-5-one ([3H]PSB-11), a novel high-affinity antagonist radioligand for human A3 adenosine receptors Bioorg. Med. Chem. Lett. 12 2002 501 503 (Pubitemid 34113933)
183. O. Lenzi, V. Colotta, D. Catarzi, F. Varano, D. Poli, G. Filacchioni, K. Varani, F. Vicenzi, P.A. Borea, S. Paoletta, E. Morizzo, and S. Moro 2-Phenylpyrazolo[4,3-d]pyrimidin-7-one as a new scaffold to obtain potent and selective human A3 adenosine receptor antagonists: new insights into the receptor-antagonist recognition J. Med. Chem. 52 2009 7640 7652
184. 3 adenosine receptor antagonists Bioorg. Med. Chem. 17 2009 3733 3738
185. 1 receptors J. Pharmacol. Sci. 96 2004 42 52 (Pubitemid 39318777)
186. 3H]KF17837S, a selective adenosine A2 receptor antagonist, to rat brain membranes Mol. Pharmacol. 46 1994 817 822 (Pubitemid 24364092)
187. C.E. Müller, J. Hipp, U. Schobert, W. Frobenius, M. Pawlowski, F. Suzuki, and J. Sandoval-Ramírez Synthesis and structure-activity relationships of 3,7-dimethyl-1-propargylxanthine derivatives, A2A-selective adenosine receptor antagonists J. Med. Chem. 40 1997 4396 4405 (Pubitemid 28042319)
188. 2A Adenosine receptor antagonists - future drugs for Parkinson's disease? Drugs Fut. 25 2000 1043 1052
189. A.-H. Li, S. Moro, N. Forsyth, N. Melman, X.-D. Ji, and K.A. Jacobson Synthesis, CoMFA analysis, and receptor docking of 3,5-diacyl-2,4- dialkylpyridine derivatives as selective A3 adenosine receptor antagonists J. Med. Chem. 42 1999 706 721 (Pubitemid 29110786)
190. 2A receptors in rats Synapse 42 2001 164 176 (Pubitemid 32999623)
191. W. Al Jaroudi, and A.E. Iskandrian Regadenoson: a new myocardial stress agent J. Am. Coll. Cardiol. 54 2009 1123 1130
192. 2B adenosine receptor antagonist. ACS Med. Chem. Lett. 1 (in press) doi:10.1021/ml100249e.